Clinical Study
Outcome for Patients with Triple-Negative Breast Cancer Is Not Dependent on Race/Ethnicity
Table 1
Distribution of patient, clinicopathologic, and socioeconomic characteristics of 202 Patients with triple negative breast cancer.
| | African-American | Caucasian | value | | () | () | | | 68% | 32% | |
| | Characteristics | | | |
| | Mean age years (range) | 54 (28–33) | 60 (36–87) | 0.38 |
| | Mean tumor size (cm) | 3.39 | 3.16 | 0.35 |
| | Tumor size distribution | | | | | T1 (28%) | 33 (24%) | 24 (38%) | | | T2 (53%) | 76 (55%) | 30 (47%) | 0.25 | | T3 (13%) | 19 (14%) | 7 (11%) | | | T4 (6%) | 10 (7%) | 3 (4%) | |
| | Nodal distribution | | | | | N0 (55%) | 71 (51%) | 40 (62%) | | | N1 (25%) | 37 (27%) | 14 (22%) | 0.5 | | N2 (15%) | 23 (17%) | 7 (11%) | | | N3 (5%) | 7 (5%) | 3 (5%) | |
| | Stage distribution | | | | | Stage 1 (21%) | 25 (18%) | 17 (26%) | | | Stage 2 (52%) | 73 (53%) | 33 (52%) | 0.31 | | Stage 3 (27%) | 40 (29%) | 14 (22%) | |
| | Tumor grade | | | | | I/II (38%) | 40/125 (32%) | 29/59 (49%) | 0.04 | | III (62%) | 85/125 (68%) | 30/59 (51%) | |
| | Definitive surgery | | | | | Breast-conserving Rx (31%) | 51 (37%) | 12 (19%) | 0.01 | | Mastectomy (69%) | 87 (63%) | 52 (81%) | |
| | Systemic treatment | | | | | Adriamycin alone (19%) | 28 (20%) | 11 (17%) | | | Adriamycin + Taxane (41%) | 60 (44%) | 22 (34%) | | | Taxane alone (3%) | 3 (2%) | 3 (5%) | 0.33 | | Hormone therapy alone (3%) | 2 (1%) | 3 (5%) | | | Hormone therapy + chemotherapy (16%) | 19 (14%) | 14 (22%) | | | Others (18%) | 26 (19%) | 11 (17%) | |
| | Median annual income | $16,493 | $16,667 | | | Mean (range) annual income | $17,873 | $21,081 | <0.001 | | ($15,367–$36,772) | ($15,795–$36,787) | |
| | Financial class | | | |
| | Commercial (11%) | 8/80 (10%) | 5/35 (14%) | |
| | Medicare (10%) | 7/80 (9%) | 4/35 (11%) | 0.69 |
| | Medicaid (6%) | 6/80 (7%) | 1/35 (3%) | |
| | Free care (73%) | 59/80 (74%) | 25/35 (72%) | |
|
|
